Hyman B. Muss

Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907)

H. J. Cohen, K. J. Ruddy, C. A. Hudis, Hyman B. Muss et autres

Cyclophosphamide-methotrexate-5-fluorouracil (CMF) is often selected as adjuvant chemotherapy for older patients with early-stage breast cancer due to perceived superior tolerability. We sought to measure persistence with CMF, adherence to oral cyclophosphamide, and the association of these with toxic effects.

A phase II study of dibromodulcitol (DBD) in Stage IV melanoma

Judy Hopkins, Frederick Richards, Douglas Case, Ellen K. Pope et autres

Twenty-four patients were evaluated in a non-randomized study to assess the effectiveness of dibromodulcitol (DBD) in Stage IV melanoma. Patients received 100 mg/m2 of DBD orally for 35 days. The dose was escalated to 130 mg/m2 and then to 160 mg/m2 if …

us (code pays fourni par la source)